Source: Contract Pharma

Juventas: CASI Acquires Anti-CD19 T-cell Therapy from Juventas

In lieu of the upfront payment, CASI Pharmaceuticals (Wuxi) Co., will invest approximately $11.6 million in Juventas

Read full article »
Juventas's Competitors | Juventas's News | Juventas's Financials
Stay up-to-date with the latest news on Juventas
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Rahul Aras's photo - President & CEO of Juventas

President & CEO

Rahul Aras

CEO Approval Rating

72/100

Read more
Stay up-to-date with the latest news on Juventas